Why the study?
Understanding of the impact of frailty on heart failure aetiology and treatments is still emerging, and physiological changes from frailty can limit optimization of pharmacotherapy.
Design
Narrative review
Key result
Physiological changes due to biological ageing and frailty can limit the optimization of heart failure pharmacotherapy, impacting its pharmacodynamics, pharmacokinetics, effectiveness, and safety.
Authors
Loading...
Frailty heightens adverse event risks limiting HF pharmacotherapy optimization; leaves open frailty-adjusted regimens for advanced disease.
Frailty alters the pharmacokinetics and pharmacodynamics of heart failure medications, highlighting the need to integrate frailty assessment into heart failure management.
Duong et al. (2026) conducted a review in Heart failure and frailty. Heart failure pharmacotherapy was evaluated. Physiological changes due to biological ageing and frailty can limit the optimization of heart failure pharmacotherapy, impacting its pharmacodynamics, pharmacokinetics, effectiveness, and safety.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: